To schedule a new patient appointment call 732-253-3939 or 844-CANCERNJ (844-226-2376).
For all other inquiries call 732-235-2465.
As a Board-certified Radiation Oncologist, I am a Professor in the Department of Radiation Oncology at the Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School (RWJMS). I graduated Magna Cum Laude from an accelerated physician-scientist (BS/MD) program from Rensselaer Polytechnic Institute. I then went on to receive my medical degree from Albany Medical College in Albany, New York where I graduated with a distinction in research. Soon after, I returned to my home state of New Jersey and went on to complete my internship in Internal Medicine at Robert Wood Johnson Medical School. I continued my residency in Radiation Oncology at Robert Wood Johnson Medical School / Cancer Institute of New Jersey where I held the title of Chief Resident Physician.
Prior to joining the faculty at Rutgers Cancer Institute of New Jersey, I served as the Director of Proton Therapy at the Icahn School of Medicine at Mount Sinai in New York City, where I specialized in the treatment of Lymphoma / Hematologic Malignancies and Adult and Pediatric Brain tumors.
I have had the opportunity to conduct several clinical trials and present and co-author numerous clinical and translational papers in the oncology literature. My clinical and academic interests are to integrate patient reported outcomes to improve cancer care delivery and the health-related quality of life of cancer patients. I strive to optimize the use of intensity-modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), as well as proton beam therapy (PBT) in the management of my cancer patients.
Currently, I serve as Director of Proton Beam Therapy at the Laurie Proton Therapy Center with Robert Wood Johnson University Hospital in partnership with the Rutgers Cancer Institute of New Jersey. With this position, I have helped to integrate the use of proton therapy into the multidisciplinary oncology treatment programs within the cancer center and across the Robert Wood Johnson Barnabas Health System. At Rutgers Cancer Institute of New Jersey, my primary research and clinical focus is in pediatric cancers, lymphoma / hematologic malignancies, genitourinary malignancies and several disease sites using proton beam therapy (including pediatrics, skull base tumors, brain tumors-benign and malignant). I have a strong research interest in the outcomes of patients treated with advanced radiotherapy modalities. I am also the Fellowship Director for the Precision Radiation Oncology training program, aimed to provide specialty training for international radiation oncology graduates.
In addition to my clinical and academic practice at Rutgers Cancer Institute of New Jersey, I hold several national and international leadership roles within committees in ASTRO (American Society for Therapeutic Radiation Oncology), steering committee member of the International Lymphoma Radiation Oncology Group (ILROG), and on several committees of the Particle Therapy Co-Operative Group (PTCOG), American Society for Clinical Oncology (ASCO), and American Radium Society (ARS). I am also an active member of several co-operative groups including: Radiation Therapy Oncology Group (RTOG), Proton Collaborative Group (PCG), and Children's Oncology Group (COG). I also serve as an active peer reviewer and on the editorial board for several oncology focused journals, including the Journal of Clinical Oncology and International Journal of Radiation Oncology, Biology, and Physics.
In addition to the above, I have had the opportunity to obtain a Master of Business Administration with a focus in Strategic Leadership.
Pediatric cancers, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myeloma, Leukemia, Prostate cancer, Bladder Cancer, Testicular Cancer, Intensity-modulated Radiation Therapy (IMRT), Tomotherapy, Image-guided Radiation Therapy (IGRT), Proton Beam Therapy (PBT), Stereotactic Radiosurgery (SRS), Stereotactic Body Radiotherapy (SBRT).
March 24, 2025
Well treated - very good care.
March 17, 2025
Everyone provided me with excellent care and treated me with respect and compassion. Thank you.
February 11, 2025
Appreciate every efforts made from the team.
November 13, 2024
Everyone was EXCEPTIONAL.
November 5, 2024
Treated well -
September 20, 2024
Dr. Parikh, PA Carl Michael and Martha RN. Best team ever.
July 24, 2024
Dr. Parikh is one of the most caring doctors I see and his staff is superior.
Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with your insurance company they are still a participating plan prior to receiving services or care. Each plan is different and some provide different levels of coverage that could make a difference in your out-of-pocket costs. It is always best for the patient receiving care to contact their insurance company to obtain more information.
In what is believed to be the largest dataset study to date examining the role of race on survival outcomes for pediatric patients with Hodgkin lymphoma, Dr. Rahul R. Parikh and investigators at Rutgers Cancer Institute of New Jersey have found that black patients have significantly worse overall survival at five years than white patients when accounting for all available clinical variables. Learn more
